Success is hard to come by in drug development. “On average, 50% of phase III trials with novel therapeutics fail,” says Subha Madhavan, vice president and head of AI/ML at Pfizer. “A primary reason ...
Vol. 38, No. 3, Special Issue: Analysis of Covariance (Sep., 1982), pp. 651-660 (10 pages) When a treatment influences both the primary response and the covariate, a standard analysis of covariance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback